Aktuellt
SENASTE
Redeye maintains a positive outlook on Nanologica following the company's latest positive press release confirming the first order under the existing agreement with Yunbo Technologies, valued at approximately USD14m over six years for the supply of silica. According to the CEO, production has stabilized, and ongoing production with increasing volumes is expected from Q1. H2 2023 has contained tangible sales-related progress on several fronts yet to be appreciated by the share price, which we argue bodes well for a positive development in 2024. Our base case stands at SEK16.
LÄS MER
